Targeting of adenosine receptors in ischemiareperfusion injury

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 1, 2011, Pages 103-118

  Laubach, Victor E ^a   French, Brent A ^a   Okusa, Mark D ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Inflammation; Innate immunity; Preconditioning; Therapeutic targets; Transplantation

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 8 [4 (2 AMINOETHYLCARBAMOYL)METHOXYPHENYL] 1,3 DIPROPYLXANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE DEAMINASE; ADENOSINE RECEPTOR A2B; ADENOSINE RECEPTOR A3; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; APADENOSON; ATL 313; BRADYKININ; CXCL1 CHEMOKINE; HYPOXIA INDUCIBLE FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; OPIATE; RANTES; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADENOSINE DEAMINASE DEFICIENCY; ANTIINFLAMMATORY ACTIVITY; CELL DAMAGE; CELL MIGRATION; CHEMOTAXIS; DENDRITIC CELL; DRUG HALF LIFE; DRUG TARGETING; ENDOTHELIUM; FIBROBLAST; GENE EXPRESSION; GLUCONEOGENESIS; GLYCOGENOLYSIS; GRAFT DYSFUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART INJURY; HEART MUSCLE CELL; HEART PROTECTION; HEMATOPOIETIC CELL; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; ISCHEMIA; ISCHEMIC PRECONDITIONING; KIDNEY INJURY; LIVER CELL; LIVER INJURY; LIVER PROTECTION; LUNG INJURY; LUNG TRANSPLANTATION; MACROPHAGE; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; RENAL PROTECTION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; UREA CYCLE;

ADENOSINE; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INFLAMMATION; PURINERGIC P1 RECEPTOR AGONISTS; PURINERGIC P1 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P1; REPERFUSION INJURY;

EID: 78650190505     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2011.541441     Document Type: Review

References (163)

1. Fiser SM, Tribble CG, Long SM, et al. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 2002;73:1041-7
2. Neary P, Redmond HP. Ischaemia-reperfusion injury and the systemic inflammatory response syndrome. In: Grace PA, Mathie RT, editors, Ischaemia-reperfusion injury. Blackwell Science, Oxford; 1999. p. 123-36
3. Bahde R, Spiegel HU. Hepatic ischaemia-reperfusion injury from bench to bedside. Br J Surg 2010;97:1461-75
4. Kharbanda RK. Cardiac conditioning: A review of evolving strategies to reduce ischaemia-reperfusion injury. Heart 2010;96:1179-86
5. Kin H, Zatta AJ, Lofye MT, et al. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 2005;67:124-33
6. Liu GS, Thornton J, Van Winkle DM, et al. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 1991;84:350-6
7. Yang XM, Philipp S, Downey JM, Cohen MV. Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol 2005;100:57-63
8. Dirksen MT, Laarman GJ, Simoons ML, Duncker DJ. Reperfusion injury in humans: A review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc Res 2007;74:343-55
9. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-81
10. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007;14:1315-23
11. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 2000;362:299-309
12. Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res 2004;61:461-70
13. Li C, Jackson RM. Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol 2002;282:C227-41
14. Collard CD, Lekowski R, Jordan JE, et al. Complement activation following oxidative stress. Mol Immunol 1999;36:941-8
15. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002;105:656-62
16. Li L, Huang L, Sung SS, et al. The chemokine receptors CCR2 and CX3CR1 mediate monocyte/ macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int 2008;74:1526-37
17. Kaczorowski DJ, Tsung A, Billiar TR. Innate immune mechanisms in ischemia/reperfusion. Front Biosci (Elite Ed) 2009;1:91-8
18. Farhood A, McGuire GM, Manning AM, et al. Intercellular adhesion molecule 1 (ICAM-1) expression and its role in neutrophil-induced ischemia-reperfusion injury in rat liver. J Leukoc Biol 1995;57:368-74
19. Lefer AM, Weyrich AS, Buerke M. Role of selectins, a new family of adhesion molecules, in ischaemia-reperfusion injury. Cardiovasc Res 1994;28:289-94 (Pubitemid 24131064)
20. Okusa MD, Linden J, Huang L, et al. A2A-adenosine receptor mediated inhibition of renal injury and neutrophil adhesion. Am J Physiol 2000;279:F809-18
21. Li L, Okusa MD. Macrophages, dendritic cells, and kidney ischemia-reperfusion injury. Semin Nephrol 2010;30:268-77
22. Ysebaert DK, De Greef KE, Vercauteren SR, et al. Identification and kinetics of leukocytes after severe ischaemia/reperfusion renal injury. Nephrol Dial Transplant 2000;15:1562-74
23. Linfert D, Chowdhry T, Rabb H. Lymphocytes and ischemia-reperfusion injury. Transplant Rev (Orlando) 2009;23:1-10
24. Breda MA, Drinkwater DC, Laks H, et al. Prevention of reperfusion injury in the neonatal heart with leukocyte-depleted blood. J Thorac Cardiovasc Surg 1989;97:654-65
25. Zhao M, Fernandez LG, Doctor A, et al. Alveolar macrophage activation is a key initiation signal for acute lung ischemia-reperfusion injury. Am J Physiol Lung Cell Mol Physiol 2006;291:L1018-26
26. Yokota N, Daniels F, Crosson J, Rabb H. Protective effect of T cell depletion in murine renal ischemia-reperfusion injury. Transplantation 2002;74:759-63
27. Yamauchi-Takihara K, Ihara Y, Ogata A, et al. Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation 1995;91:1520-4
28. Sharma AK, Fernandez LG, Awad AS, et al. Proinflammatory response of alveolar epithelial cells is enhanced by alveolar macrophage-produced TNF-alpha during pulmonary ischemia-reperfusion injury. Am J Physiol Lung Cell Mol Physiol 2007;293:L105-13
29. Osborne DL, Aw TY, Cepinskas G, Kvietys PR. Development of ischemia/ reperfusion tolerance in the rat small intestine. An epithelium-independent event. J Clin Invest 1994;94:1910-18
30. Peralta C, Hotter G, Closa D, et al. Protective effect of preconditioning on the injury associated to hepatic ischemia-reperfusion in the rat: Role of nitric oxide and adenosine. Hepatology 1997;25:934-7
31. Heurteaux C, Lauritzen I, Widmann C, Lazdunski M. Essential role of adenosine, adenosine A1 receptors, and ATP-sensitive K+ channels in cerebral ischemic preconditioning. Proc Natl Acad Sci USA 1995;92:4666-70
32. Du ZY, Hicks M, Winlaw D, et al. Ischemic preconditioning enhances donor lung preservation in the rat. J Heart Lung Transplant 1996;15:1258-67
33. Islam CF, Mathie RT, Dinneen MD, et al. Ischaemia-reperfusion injury in the rat kidney: The effect of preconditioning. Br J Urol 1997;79:842-7
34. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: United at reperfusion. Pharmacol Ther 2007;116:173-91
35. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: Taking a RISK for cardioprotection. Heart Fail Rev 2007;12:217-34
36. Hausenloy DJ, Yellon DM. Time to take myocardial reperfusion injury seriously. N Engl J Med 2008;359:518-20
37. Morin D, Assaly R, Paradis S, Berdeaux A. Inhibition of mitochondrial membrane permeability as a putative pharmacological target for cardioprotection. Curr Med Chem 2009;16:4382-98
38. Downey JM, Liu GS, Thornton JD. Adenosine and the anti-infarct effects of preconditioning. Cardiovasc Res 1993;27:3-8
39. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am J Physiol-Heart Circul Physiol 2003;285:H579-88
40. Kaur S, Jaggi AS, Singh N. Molecular aspects of ischaemic postconditioning. Fundam Clin Pharmacol 2009;23:521-36
41. Kerendi F, Kin H, Halkos ME, et al. Remote postconditioning. Brief renal ischemia and reperfusion applied before coronary artery reperfusion reduces myocardial infarct size via endogenous activation of adenosine receptors. Basic Res Cardiol 2005;100:404-12
42. Tapuria N, Kumar Y, Habib MM, et al. Remote ischemic preconditioning: A novel protective method from ischemia reperfusion injury - a review. J Surg Res 2008;150:304330
43. Hershfield MS. New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol 2005;35:25-30
44. Fredholm BB, Jzerman AP, Jacobson KA, et al. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-552
45. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: Therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008;7:759-70
46. Fredholm BB, Irenius E, Kull B, Schulte G. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 2001;61:443-8
47. Londos C, Wolff J, Cooper DMF. Adenosine receptors and adenylate cyclase interactions. In: Berne RM, Rall TW, Rubio R, editors. Regulatory function of adenosine. Martinus Nijhoff; Boston; 1982:17-32
48. Thiel M, Caldwell CC, Sitkovsky MV. The critical role of adenosine A2A receptors in downregulation of inflammation and immunity in the pathogenesis of infectious diseases. Microbes Infect 2003;5:515-26
49. Eltzschig HK, Ibla JC, Furuta GT, et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: Role of ectonucleotidases and adenosine A2B receptors. J Exp Med 2003;198:783-96
50. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5:247-64
51. Fan M, Qin W, Mustafa SJ. Characterization of adenosine receptor(s) involved in adenosine-induced bronchoconstriction in an allergic mouse model. Am J Physiol Lung Cell Mol Physiol 2003;284:L1012-19
52. Salvatore CA, Jacobson MA, Taylor HE, et al. Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci USA 1993;90:10365-9
53. Linden J. Molecular approach to adenosine receptors: Receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 2001;41:775-87
54. Hsu K, Wang D, Wu SY, et al. Ischemia-reperfusion lung injury attenuated by ATP-MgCl2 in rats. J Appl Physiol 1994;76:545-52
55. Blackburn MR, Vance CO, Morschl E, Wilson CN. Adenosine receptors and inflammation. Handb Exp Pharmacol 2009;193:215-69
56. Cronstein BN, Daguma L, Nichols D, et al. The adenosine/neutrophil paradox resolved: Human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2- generation, respectively. J Clin Invest 1990;85:1150-7
57. Yang Z, Cerniway RJ, Byford AM, et al. Cardiac overexpression of A1-adenosine receptor protects intact mice against myocardial infarction. Am J Physiol Heart Circ Physiol 2002;282:H949-55
58. Lee HT, Xu H, Nasr SH, et al. A1 adenosine receptor knockout mice exhibit increased renal injury following ischemia and reperfusion. Am J Physiol Renal Physiol 2004;286:F298-306
59. Neely CF, Keith IM. A1 adenosine receptor antagonists block ischemia-reperfusion injury of the lung. Am J Physiol 1995;268:L1036-46
60. Gazoni LM, Walters DM, Unger EB, et al. Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg 2010;140:440-6
61. Yildiz G, Demiryurek AT, Gumusel B, Lippton H. Ischemic preconditioning modulates ischemia-reperfusion injury in the rat lung: Role of adenosine receptors. Eur J Pharmacol 2007;556:144-50
62. Gallos G, Ruyle TD, Emala CW, Lee HT. A1 adenosine receptor knockout mice exhibit increased mortality, renal dysfunction, and hepatic injury in murine septic peritonitis. Am J Physiol Renal Physiol 2005;289:F369-76
63. Ngamsri KC, Wagner R, Vollmer I, et al. Adenosine receptor A1 regulates polymorphonuclear cell trafficking and microvascular permeability in lipopolysaccharide-induced lung injury. J Immunol 2010;185:4374-84
64. Neely CF, Jin J, Keith IM. A1-adenosine receptor antagonists block endotoxin-induced lung injury. Am J Physiol 1997;272:L353-61
65. Khimenko PL, Moore TM, Hill LW, et al. Adenosine A2 receptors reverse ischemia-reperfusion lung injury independent of beta-receptors. J Appl Physiol 1995;78:990-6
66. Rieger JM, Brown ML, Sullivan GW, et al. Design, synthesis, and evaluation of novel A2A adenosine receptor agonists. J Med Chem 2001;44:531-9
67. Sharma AK, Linden J, Kron IL, Laubach VE. Protection from pulmonary ischemia-reperfusion injury by adenosine A2A receptor activation. Respir Res 2009;10:58
68. Gazoni LM, Laubach VE, Mulloy DP, et al. Additive protection against lung ischemia-reperfusion injury by adenosine A2A receptor activation before procurement and during reperfusion. J Thorac Cardiovasc Surg 2008;135:156-65
69. Sharma AK, Laubach VE, Ramos SI, et al. Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg 2010;139:474-82
70. Rivo J, Zeira E, Galun E, et al. Attenuation of reperfusion lung injury and apoptosis by A2A adenosine receptor activation is associated with modulation of Bcl-2 and Bax expression and activation of extracellular signal-regulated kinases. Shock 2007;27:266-73
71. Reece TB, Ellman PI, Maxey TS, et al. Adenosine A2A receptor activation reduces inflammation and preserves pulmonary function in an in vivo model of lung transplantation. J Thorac Cardiovasc Surg 2005;129:1137-43
72. Cagnina RE, Ramos SI, Marshall MA, et al. Adenosine A2B receptors are highly expressed on murine type II alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2009;297:L467-74
73. St Hilaire C, Koupenova M, Carroll SH, et al. TNF-alpha upregulates the A2B adenosine receptor gene: The role of NAD(P)H oxidase 4. Biochem Biophys Res Commun 2008;375:292-6
74. Anvari F, Sharma AK, Fernandez LG, et al. Tissue-derived proinflammatory effect of adenosine A2B receptor in lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg 2010;140:871-7
75. Kolachala VL, Vijay-Kumar M, Dalmasso G, et al. A2B adenosine receptor gene deletion attenuates murine colitis. Gastroenterology 2008;135:861-70
76. Zhong H, Belardinelli L, Maa T, Zeng D. Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol 2005;32:2-8
77. Zhong H, Wu Y, Belardinelli L, Zeng D. A2B adenosine receptors induce IL-19 from bronchial epithelial cells, resulting in TNF-alpha increase. Am J Respir Cell Mol Biol 2006;35:587-92
78. Schingnitz U, Hartmann K, Macmanus CF. Signaling through the A2B adenosine receptor dampens endotoxin-induced acute lung injury. J Immunol 2010;184:5271-9
79. Rivo J, Zeira E, Galun E, Matot I. Activation of A3 adenosine receptor provides lung protection against ischemia-reperfusion injury associated with reduction in apoptosis. Am J Transplant 2004;4:1941-8
80. Matot I, Weiniger CF, Zeira E, et al. A3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. Crit Care 2006;10:R65
81. Matot I, Einav S, Weiniger CF, et al. Lung injury after in vivo reperfusion: Outcome at 27 hours after reperfusion. Anesthesiology 2008;109:269-78
82. Morschl E, Molina JG, Volmer JB, et al. A3 adenosine receptor signaling influences pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol 2008;39:697-705
83. Wagner R, Ngamsri KC, Stark S, et al. Adenosine receptor A3 is a critical mediator in LPS-induced pulmonary inflammation. Am J Physiol Lung Cell Mol Physiol 2010;299:L502-12
84. Spielman WS, Arend LJ. Adenosine receptors and signaling in the kidney. Hypertension 1991;17:117-30
85. Vallon V, Muhlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev 2006;86:901-40
86. Vallon V, Osswald H. Adenosine receptors and the kidney. Handb Exp Pharmacol 2009:443-470
87. Gouyon J-B, Guignard J-P. Theophylline prevents the hypoxemia-induced renal hemodynamic changes in rabbits. Kidney Int 1988;33:1078-83
88. Lin J-J, Churchill PC, Bidani AK. Effect of theophylline on the initiation phase of postischemic acute renal failure. J Lab Clin Med 1986;108:150-4
89. Grenz A, Zhang H, Eckle T, et al. Protective role of ecto-5'-nucleotidase (CD73) in renal ischemia. J Am Soc Nephrol 2007;18:833-45
90. Grenz A, Zhang H, Hermes M, et al. Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J 2007;21:2863-73
91. Joo JD, Kim M, Horst P, et al. Acute and delayed renal protection against renal ischemia and reperfusion injury with A1 adenosine receptors. Am J Physiol Renal Physiol 2007;293:F1847-57
92. Lee HT, Emala CW. Protective effects of renal ischemic preconditioning and adenosine pretreatment: Role of A1 and A3 receptors. Am J Physiol Renal Physiol 2000;278:F380-7
93. Kim M, Chen SW, Park SW, et al. Kidney-specific reconstitution of the A1 adenosine receptor in A1 adenosine receptor knockout mice reduces renal ischemia-reperfusion injury. Kidney Int 2009;75:809-23
94. Lee HT, Kim M, Jan M, et al. Renal tubule necrosis and apoptosis modulation by A1 adenosine receptor expression. Kidney Int 2007;71:1249-61
95. Gill A, Wortham K, Costa D, et al. Protective effect of tonapofylline (BG9928), an adenosine A1 receptor antagonist, against cisplatin-induced acute kidney injury in rats. Am J Nephrol 2009;30:521-6
96. Lee HT, Jan M, Bae SC, et al. A1 adenosine receptor knockout mice are protected against acute radiocontrast nephropathy in vivo. Am J Physiol Renal Physiol 2006;290:F1367-75
97. Li L, Okusa MD. Blocking the immune respone in ischemic acute kidney injury: The role of adenosine 2A agonists. Nat Clin Pract Nephrol 2006;2:432-44
98. Okusa MD, Linden J, Macdonald T, Huang L. Selective A2A-adenosine receptor activation during reperfusion reduces ischemia-reperfusion injury in rat kidney. Am J Physiol 1999;277:F404-12
99. Okusa MD, Linden J, Huang L, et al. Enhanced protection from renal ischemia-reperfusion injury with A2A-adenosine receptor activation and PDE 4 inhibition. Kidney Int 2001;59:2114-25
100. Awad AS, Rouse M, Huang L, et al. Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury. Kidney Int 2009:689-698
101. Day Y-J, Huang L, McDuffie MJ, et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest 2003;112:883-91
102. Grenz A, Osswald H, Eckle T, et al. The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Med 2008;5:e137
103. Lee HT, Ota-Setlik A, Xu H, et al. A3 adenosine receptor knockout mice are protected against ischemia- and myoglobinuria-induced renal failure. Am J Physiol Renal Physiol 2003;284:F267-73
104. Lee HT, Kim M, Joo JD, et al. A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. Am J Physiol Regul Integr Comp Physiol 2006;291:R959-69
105. Grden M, Podgorska M, Szutowicz A, Pawelczyk T. Altered expression of adenosine receptors in heart of diabetic rat. J Physiol Pharmacol 2005;56:587-97
106. Epperson SA, Brunton LL, Ramirez-Sanchez I, Villarreal F. Adenosine receptors and second messenger signaling pathways in rat cardiac fibroblasts. Am J Physiol Cell Physiol 2009;296:C1171-7
107. Auchampach JA, Bolli R. Adenosine receptor subtypes in the heart: Therapeutic opportunities and challenges. Am J Physiol Heart Circ Physiol 1999;276:H1113-16
108. Toombs CF, McGee S, Johnston WE, Vinten-Johansen J. Myocardial protective effects of adenosine. Infarct size reduction with pretreatment and continued receptor stimulation during ischemia. Circulation 1992;86:986-994
109. Thornton JD, Liu GS, Olsson RA, Downey JM. Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction. Circulation 1992;85:659-65
110. Zhao ZQ, Sato H, Williams MW, et al. Adenosine A2-receptor activation inhibits neutrophil-mediated injury to coronary endothelium. Am J Physiol Heart Circ Physiol 1996;271:H1456-64
111. Jordan JE, Thourani VH, Auchampach JA, et al. A3 adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury. Am J Physiol Heart Circ Physiol 1999;277:H1895-905
112. Philipp S, Yang X-M, Cui L, et al. Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc Res 2006;70:308-14
113. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-36
114. Downey J, Davis A, Cohen M. Signaling pathways in ischemic preconditioning. Heart Fail Rev 2007;12:181-8
115. Gross ER, Gross GJ. Ischemic preconditioning and myocardial infarction: An update and perspective. Drug Discov Today: Dis Mech 2007;4:165-74
116. Yellon DM, Downey JM. Preconditioning the myocardium: From cellular physiology to clinical cardiology. Physiol Rev 2003;83:1113-51
117. Matherne GP, Linden J, Byford AM, et al. Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia. Proc Natl Acad Sci USA 1997;94:6541-6 (Pubitemid 27270721)
118. Olafsson B, Forman MB, Puett DW, et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: Importance of the endothelium and the no- reflow phenomenon. Circulation 1987;76:1135-45
119. Babbitt DG, Virmani R, Vildibill HD Jr, et al. Intracoronary adenosine administration during reperfusion following 3 hours of ischemia: Effects on infarct size, ventricular function, and regional myocardial blood flow. Am Heart J 1990;120:808-18
120. Jordan JE, Zhao ZQ, Sato H, et al. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther 1997;280:301-9
121. Nakamura M, Zhao Z-Q, Clark KL, et al. A novel adenosine analog, AMP579, inhibits neutrophil activation, adherence and neutrophil-mediated injury to coronary vascular endothelium. Eur J Pharmacol 2000;397:197-205
122. Lasley RD, Jahania MS, Mentzer RM Jr. Beneficial effects of adenosine A2a agonist CGS-21680 in infarcted and stunned porcine myocardium. Am J Physiol Heart Circ Physiol 2001;280:H1660-6
123. Glover DK, Riou LM, Ruiz M, et al. Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A2A receptor agonist, in reperfused canine myocardium. Am J Physiol Heart Circ Physiol 2005;288:H1851-8
124. Schlack W, Schafer M, Uebing A, et al. Adenosine-A2-receptor activation at reperfusion reduces infarct size and improves myocardial wall function in dog heart. J Cardiovasc Pharmacol 1993;22:89-96
125. Norton ED, Jackson EK, Turner MB, et al. The effects of intravenous infusions of selective adenosine-A1-receptor and A2-receptor agonists on myocardial reperfusion injury. Am Heart J 1992;123:332-8
126. Dai W, Hale SL, Nayak R, Kloner RA. ATL 313, a selective A2A adenosine receptor agonist, reduces myocardial infarct size in a rat ischemia/reperfusion model. Open Cardiovasc Med J 2009;3:166-72
127. Yang Z, Day Y-J, Toufektsian M-C, et al. Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 2005;111:2190-7
128. Yang Z, Day Y-J, Toufektsian M-C, et al. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation 2006;114:2056-64
129. Granfeldt A, Lefer DJ, Vinten-Johansen J. Protective ischaemia in patients: Preconditioning and postconditioning. Cardiovasc Res 2009;83:234-46
130. Morrison RR, Tan XL, Ledent C, et al. Targeted deletion of A2A adenosine receptors attenuates the protective effects of myocardial postconditioning. Am J Physiol Heart Circ Physiol 2007;293:H2523-9
131. Kuno A, Solenkova NV, Solodushko V, et al. Infarct limitation by a protein kinase G activator at reperfusion in rabbit hearts is dependent on sensitizing the heart to A2b agonists by protein kinase C. Am J Physiol Heart Circ Physiol 2008;295:H1288-95
132. Xi J, McIntosh R, Shen X, et al. Adenosine A2A and A2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts. J Mol Cell Cardiol 2009;47:684-90
133. Methner C, Schmidt K, Cohen MV, et al. Both A2a and A2b adenosine receptors at reperfusion are necessary to reduce infarct size in mouse hearts. Am J Physiol Heart Circ Physiol 2010;299:H1262-4
134. Zhao ZQ, Nakanishi K, McGee DS, et al. A1 receptor mediated myocardial infarct size reduction by endogenous adenosine is exerted primarily during ischaemia. Cardiovasc Res 1994;28:270-9
135. Baxter GF, Hale SL, Miki T, et al. Adenosine A1 agonist at reperfusion trial (AART): Results of a three-center, blinded, randomized, controlled experimental infarct study. Cardiovasc Drugs Ther 2000;14:607-14
136. Auchampach JA, Ge Z-D, Wan TC, et al. A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs. Am J Physiol Heart Circ Physiol 2003;285:H607-13
137. Maddock HL, Mocanu MM, Yellon DM. Adenosine A3 receptor activation protects the myocardium from reperfusion/reoxygenation injury. Am J Physiol Heart Circ Physiol 2002;283:H1307-13
138. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998;50:413-92
139. Todo S, Zhu Y, Zhang S, et al. Attenuation of ischemic liver injury by augmentation of endogenous adenosine. Transplantation 1997;63:217-23 (Pubitemid 27121201)
140. Leon Fernandez OS, Ajamieh HH, Berlanga J, et al. Ozone oxidative preconditioning is mediated by A1 adenosine receptors in a rat model of liver ischemia/ reperfusion. Transpl Int 2008;21:39-48
141. Ajamieh HH, Candelario-Jalil E, Fernandez OS, Gerbes AL. Ischaemic and pharmacological preconditionings protect liver via adenosine and redox status following hepatic ischaemia/ reperfusion in rats. Clin Sci (Lond) 2008;115:69-77
142. Kim J, Kim M, Song JH, Lee HT. Endogenous A1 adenosine receptors protect against hepatic ischemia reperfusion injury in mice. Liver Transpl 2008;14:845-54
143. Magata S, Taniguchi M, Suzuki T, et al. The effect of antagonism of adenosine A1 receptor against ischemia and reperfusion injury of the liver. J Surg Res 2007;139:7-14
144. Net M, Valero R, Almenara R, et al. The effect of normothermic recirculation is mediated by ischemic preconditioning in NHBD liver transplantation. Am J Transplant 2005;5:2385-92
145. Harada N, Okajima K, Murakami K, et al. Adenosine and selective A2A receptor agonists reduce ischemia/ reperfusion injury of rat liver mainly by inhibiting leukocyte activation. J Pharmacol Exp Ther 2000;294:1034-42
146. Cao Z, Yuan Y, Jeyabalan G, et al. Preactivation of NKT cells with alpha-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor. Am J Physiol Gastrointest Liver Physiol 2009;297:G249-58
147. Day YJ, Marshall MA, Huang L, et al. Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: Inhibition of chemokine induction. Am J Physiol Gastrointest Liver Physiol 2004;286:G285-93
148. Lappas CM, Day YJ, Marshall MA, et al. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med 2006;203:2639-48
149. Guinzberg R, Cortes D, Diaz-Cruz A, et al. Inosine released after hypoxia activates hepatic glucose liberation through A3 adenosine receptors. Am J Physiol Endocrinol Metab 2006;290:E940-51
150. Jin X, Shepherd RK, Duling BR, Linden J. Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J Clin Invest 1997;100:2849-57
151. Chhabra P, Wang K, Zeng Q, et al. Adenosine A2A agonist administration improves islet transplant outcome: Evidence for the role of innate immunity in islet graft rejection. Cell Transplant 2010;19:597-612
152. Chen JF, Pedata F. Modulation of ischemic brain injury and neuroinflammation by adenosine A2A receptors. Curr Pharm Des 2008;14:1490-9
153. Phillis JW. The effects of selective A1 and A2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res 1995;705:79-84
154. Cassada DC, Gangemi JJ, Rieger JM, et al. Systemic adenosine A2A agonist ameliorates ischemic reperfusion injury in the rabbit spinal cord. Ann Thorac Surg 2001;72:1245-50
155. Li Y, Oskouian RJ, Day YJ, et al. Mouse spinal cord compression injury is reduced by either activation of the adenosine A2A receptor on bone marrow-derived cells or deletion of the A2A receptor on non-bone marrow-derived cells. Neuroscience 2006;141:2029-39
156. Miyazaki N, Nakatsuka T, Takeda D, et al. Adenosine modulates excitatory synaptic transmission and suppresses neuronal death induced by ischaemia in rat spinal motoneurones. Pflugers Arch 2008;457:441-51
157. Ozacmak VH, Sayan H. Pretreatment with adenosine and adenosine A1 receptor agonist protects against intestinal ischemia-reperfusion injury in rat. World J Gastroenterol 2007;13:538-47
158. Hart ML, Jacobi B, Schittenhelm J, et al. Cutting Edge: A2B adenosine receptor signaling provides potent protection during intestinal ischemia/reperfusion injury. J Immunol 2009;182:3965-8
159. Xu Y, Huo Y, Toufektsian MC, et al. Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2006;290:H692-9
160. Bajwa A, Kinsey GR, Okusa MD. Immune mechanisms and novel pharmacological therapies of acute kidney injury. Curr Drug Targets 2009;10:1196-204
161. Steffens S, Montecucco F, Mach F. The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost 2009;102:240-7
162. Lappas CM, Sullivan GW, Linden J. Adenosine A2A agonists in development for the treatment of inflammation. Expert Opin Investig Drugs 2005;14:797-806
163. Yang D, Zhang Y, Nguyen HG, et al. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest 2006;116:1913-23